Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

Fabien Le Bras,Romain Bosc,Christophe Bonnet,Bohrane Slama,Manon Croix,Marie Bannier,Virginie Fataccioli,Luc Mathieu Fornecker,Lionel Tortolano,Luc Xerri,Camille Laurent,Marc André,Emmanuel Itti,Nadia Amara,Thua-Ha Dao,Romain Ricci,Philippe Gaulard,Hervé Tilly,Emmanuel Bachy,Lucie Obéric ,Patrick F Fogarty ,Alexandra Traverse‐Glehen ,Jean Marc Schiano De Colella ,Emmanuelle Nicolas‐Virelizier ,Youlia Kirova ,Corinne Haı̈oun

doi:10.1182/blood-2021-150478

Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

Fabien Le Bras, Romain Bosc + Show 24 more

Open Access

https://doi.org/10.1182/blood-2021-150478

Copy DOI

#Breast Implant Associated-Anaplastic Large-Cell Lymphoma #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

Full Text